Brief: Lipocine Announces Completion Of Dosing In Pivotal Study Of Postpartum Depression
01/05/2024 13:39
May 1 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE ANNOUNCES COMPLETION OF DOSING IN PIVOTAL STUDY
OF
POSTPARTUM DEPRESSION CANDIDATE, LPCN 1154
* LIPOCINE INC: TOPLINE RESULTS ANTICIPATED LATE IN 2Q 2024
* LIPOCINE: CONFIRMED WITH FDA ACCEPTANCE OF PROPOSAL FOR
NDA
FILING ENABLED BY PIVOTAL PK STUDY COMPARING EXPOSURE OF LPCN
1154 WITH IV INFUSION OF BREXANOLONE
Source text for Eikon: ID:nPnbj5yhla
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy